Falcão de Campos Catarina, de Carvalho Mamede
Department of Neurology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal.
Department of Neurology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal; Institute of Physiology, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.
J Clin Neurosci. 2017 Nov;45:153-154. doi: 10.1016/j.jocn.2017.08.032. Epub 2017 Sep 1.
Riluzole is the only drug approved for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS). It is well tolerated, being the most frequent adverse effects asthenia, nausea and reversible increase of liver enzymes levels. Severe adverse effects are extremely rare. We report for the first time, two patients with sporadic limb-onset ALS who developed recurrent acute pancreatitis (AP), with portal vein thrombosis as complication, during treatment with riluzole. We suggest that AP should be considered asa probable rare and severe side effect of treatment with riluzole in patients with ALS. We believe that in patients who develop AP during treatment with riluzole, its withdrawn may prevent recurrent AP and should be discussed with patients.
利鲁唑是唯一被批准用于治疗肌萎缩侧索硬化症（ALS）患者的药物。它耐受性良好，最常见的不良反应是乏力、恶心和肝酶水平可逆性升高。严重不良反应极为罕见。我们首次报告了两名散发性肢体起病的ALS患者，在使用利鲁唑治疗期间发生复发性急性胰腺炎（AP），并伴有门静脉血栓形成这一并发症。我们建议，AP应被视为ALS患者使用利鲁唑治疗可能出现的罕见且严重的副作用。我们认为，对于在使用利鲁唑治疗期间发生AP的患者，停用该药可能预防AP复发，这一点应与患者进行讨论。
